Abstract
There is a gap in consistent survivorship care in patients with cancer, especially among those with blood cancer (Gallichio et al., 2021). Survivorship begins at diagnosis, yet its inclusion in routine survivorship visits for patients with multiple myeloma (MM), chronic leukemias, and lymphomas are conspicuously absent. This is despite 5-year survival rates of at least 61% for MM, 70% for chronic leukemias, and up to 90% for certain lymphomas (National Cancer Institute, 2025).
